Refining the Diagnosis and EGFR Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and EGFR Mutation Analysis
Andrew Gordon Nicholson, David González de Castro, Pallav L. Shah et al. · Journal of Thoracic Oncology · 2010
Cited by 215 works. doi:10.1097/jto.0b013e3181c6ed9b
Authors
- Andrew Gordon Nicholson
- David González de Castro
- Pallav L. Shah
- Matthew J. Pynegar
- Alexandra J. Rice
- Sanjay Popat
References
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
- Pathology and genetics of tumours of the lung , pleura, thymus and heart
- Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
- TTF-1 Expression in Pulmonary Adenocarcinomas
- Thyroid transcription factor‐1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B
- Thyroid Transcription Factor-1 is a Marker of Lung and Thyroid Carcinomas
- Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib
- Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases